[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624476":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":91,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Assiut University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"On-Demand Therapy Group",null,"This cohort includes children with confirmed von Willebrand disease who receive treatment only during active bleeding episodes or prior to invasive procedures. Management is based on clinical indication and routine care practices, without scheduled prophylactic therapy. Bleeding frequency, treatment response, and short-term outcomes are documented during follow-up.",[13,14],"Drug: Tranexamic Acid","Drug: Von Willebrand Factor-Containing Concentrates",{"label":16,"type":10,"description":17,"interventionNames":18},"Prophylaxis Therapy Group","This cohort includes children with von Willebrand disease who experience recurrent, severe, or clinically significant bleeding and therefore receive regular prophylactic treatment with von Willebrand factor-containing concentrates. Patients are followed prospectively to assess bleeding frequency, treatment effectiveness, and clinical outcomes under scheduled preventive therapy.",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Tranexamic Acid","Tranexamic acid is used as an antifibrinolytic agent for the management of mucocutaneous bleeding episodes in children with von Willebrand disease, according to standard clinical practice.",[9,16],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Von Willebrand Factor-Containing Concentrates","Plasma-derived von Willebrand factor\u002Ffactor VIII concentrates are administered either on-demand during bleeding episodes or as regular prophylactic therapy in patients with recurrent or severe bleeding, based on clinical need.",[9,16],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Ali Maher Maher","CONTACT","01141914839","Ali.15235776@med.aun.edu.eg",[36],{"facility":37,"status":10,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Assiut university","Asyut","Egypt","EG",{"type":42,"coordinates":43},"Point",[44,45],31.18368,27.18096,{"lat":45,"lon":44},[48],{"name":5,"role":32,"phone":49,"phoneExt":10,"email":50},"08822080150","vp_grad@aun.edu.eg",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ali Maher Ebied Maher","resident at pediatric department","100624476","clinical-spectrum-and-management-of-von-willebrand-disease-among-children-in-assiut-governorate-100624476",false,"NCT07410130","Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate","Clinical Spectrum of Von Willebrand Disease Among Children: Frequency, Management, and Outcomes in Assiut Governorate","VWD-ASSIUT","Inclusion Criteria:\n\n1. Age 0-18 years.\n2. Residents of Assiut Governorate or receiving care at Assiut University Children's Hospital.\n3. Suspected or confirmed von Willebrand disease (VWD) based on clinical bleeding symptoms or referral for evaluation.\n4. Patients diagnosed with VWD using standard laboratory tests, including:\n5. VWF antigen (VWF:Ag).\n6. VWF ristocetin cofactor activity (VWF:RCo).\n7. Factor VIII activity.\n\nExclusion Criteria:\n\n1. Other inherited bleeding disorders, such as:\n2. Hemophilia A or B.\n3. Rare coagulation factor deficiencies (e.g., factors I, V, VII, X, XI deficiency).\n4. Platelet function disorders.\n5. Acquired bleeding disorders, including:\n\n   * Liver disease.\n   * Renal insufficiency.\n   * Vitamin K deficiency.\n   * Disseminated intravascular coagulation (DIC).\n   * Use of medications that may interfere with coagulation testing (e.g., anticoagulants, antiplatelet drugs).\n   * Incomplete clinical or laboratory data (for retrospective cases).\n   * Refusal of consent for participation (for prospective cases).","ALL","0 Years","18 Years",{"count":67,"type":68},25,"ESTIMATED","OBSERVATIONAL","Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting. Children with VWD may experience frequent nosebleeds, easy bruising, prolonged bleeding after injuries or surgeries, and, in adolescent girls, heavy menstrual bleeding. The severity of symptoms varies widely depending on the type of the disease and the level of the clotting factor.\n\nDespite its clinical importance, data about the frequency, clinical presentation, and treatment outcomes of von Willebrand disease among children in Upper Egypt are limited. Early recognition and appropriate management are crucial to prevent complications, reduce hospital visits, and improve quality of life.\n\nThis observational study aims to assess the frequency of von Willebrand disease among children attending Assiut University Children's Hospital, describe the different disease subtypes, and evaluate the clinical bleeding patterns and management strategies used in routine practice. The study will include children aged 0-18 years with suspected or confirmed VWD.\n\nInformation will be collected from medical records and clinical evaluations, including bleeding symptoms, laboratory test results, disease classification, and treatment approaches. The results of this study are expected to improve understanding of von Willebrand disease in children in this region and support better diagnostic and therapeutic planning for affected patients.",[72,73,74],"Von Willebrand Disease (VWD)","Inherited Bleeding Disorders in Children","Pediatric Hemostatic Disorders",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90],"Von Willebrand Disease","VWD","Pediatric bleeding disorders","Inherited coagulation disorders","Von willebrand factor","Mucocutaneous bleeding","Epistaxis in children","Menorrhagia","Bleeding assessment tool","VWD antigen","VWD activity","Hemostasis","Pediatric hematology","Factor VIII","Observational study","NOT_YET_RECRUITING","2026-02-07",{"date":94,"type":95},"2026-02-13","ACTUAL",{"date":97,"type":68},"2026-03",{"date":99,"type":68},"2026-12",{"name":5,"class":6},1]